We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Cardiac Marker POC Tests Now Widely Used in Hospitals

By LabMedica International staff writers
Posted on 04 Jan 2010
Print article
Cardiac marker point-of-care (POC) tests are now widely used in hospitals and have emerged as a successful model of the concept of point-of-care diagnostics, according to a new market report.

The 2008 world market for POC cardiac enzymes and tests is estimated at US$490 million, and growing at 12% a year for the past three years, according to healthcare market research publisher Kalorama Information (New York, NY, USA). Cardiac markers are specific enzymes or proteins that tend to be concentrated when a cardiac event is likely to occur. Brain natriuretic peptide (BNP), CK-MB (creatine kinase, muscle and brain [subunits]), myoglobin, and troponin I/T are the most commonly tested markers. Testing for these markers can effectively indicate when intervention is or is not necessary. Lab-based tests can take up to 24 hours, which has driven demand for the point-of-care products that can deliver "stat” results.

"After many years of tests to prove effectiveness, there has been the stark realization that cardiac markers are useful to rule out or rule in the variety of cardiovascular conditions that are present in an ER [emergency room],” said Shara Rosen, the report's author.

The leaders in the cardiac enzyme POC market are Inverness's (Waltham, MA, USA) Triage, Siemens Healthcare's (Erlangen, Germany) Stratus, and Roche's (Nutley, NJ, USA) POC systems (Accutrend Plus, Roche Cardiac 200, Cobas h232). Of all POC testing that occurs in hospitals, cardiac marker tests are the fastest growing segment. Also at least another 20 companies market test strips for all or one of the marker panels. These companies' rapid tests help physicians triage cardiac patients more quickly.

Point-of-care or decentralized testing has long been the standard of care for glucose, but in other areas, results have been mixed. Products have been utilized, but never in the numbers that were predicted when the technologies were developed. The growth of cardiac markers is one part of a significant trend towards the use of POC tests, which now represent 15 percent of all tests conducted in hospitals.

POC testing has expanded because of studies that demonstrate the clinical effectiveness of these tests and technologic advancements that have increased their accuracy. Kalorama's research looked at the current state of glucose testing, as well as other emerging POC test categories, including the fast growing infectious disease and cholesterol test segments.

Kalorama Information supplies independent market research in the life sciences, as well as a full range of custom research services.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.